Evolving Treatment Landscape and Future Directions n First-Line EGFR-Mutant NSCLC

Dr. Rodriguez describes the current period in EGFR-positive lung cancer as one of active change in the first-line landscape: median overall survival in recent trials has lengthened compared with historical monotherapy data, and durations of CNS disease control are now reported in the range of years. She walks through how sequencing decisions are evolving. For FLAURA2, the median OS advantage over osimertinib monotherapy is established. For MARIPOSA, median OS has not yet been finalized, projections point to similar magnitude, and intracranial DOR is reported as durable. Both combinations have shown an OS advantage over osimertinib monotherapy, which Dr. Rodriguez notes is particularly relevant for higher-risk patients with brain metastases.

She summarizes the sequencing landscape: osimertinib plus chemotherapy (FLAURA2), the chemotherapy-free EGFR-MET bispecific antibody plus tyrosine kinase inhibitor (TKI) combination amivantamab plus lazertinib (MARIPOSA), and emerging later-line options such as patritumab deruxtecan, an antibody-drug conjugate (ADC) against a different receptor. There are no head-to-head data between the two first-line combinations, but both regimens support the conclusion that monotherapy should be reserved for a select few patients, with the majority, especially younger, higher-risk patients, best served by a combination.

Dr. Rodriguez also discusses the role of the subcutaneous amivantamab formulation in administration logistics, citing the reduction in chair time and in infusion-related reactions reported in PALOMA-3, particularly for patients who live far from a cancer center. Her closing message is that regardless of regimen, the proactive conversation with patients about adverse event management (antibiotics, VTE prophylaxis, moisturizers, and topical care) is what allows dose reductions or temporary interruptions, when needed, without taking patients off effective therapy.

In the next episode, “Summary and Key Takeaways for First-Line EGFR-Mutant NSCLC With Brain Metastases,” Dr. Rodriguez summarizes the case and the broader lessons for first-line treatment selection in EGFR-positive NSCLC with brain metastases.